Project description:Alloimmune T cell mediated gastrointestinal graft-versus-host disease (GI-GVHD) occur after bone marrow translantation (BMT). GI-GVHD cause significant morbidity and mortality. Immunosuppression therapies have shown good results with adverse effects, but are still incomplete. The biology of GVHD are often understood from the immune cell perspectve, but the pathogenesis and severity from host IEC traget cell perspective remain undefined. We used next generation sequencing transcriptome to detail the gene expression of colonic epithelial cells underlying the profile changes between the syngeneic recipient and allogeneic recipient.
Project description:RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease.
PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the esophagus, stomach, small intestine, or colon.
Project description:Allogeneic hematopoietic stem cell transplantation remains the most efficacious treatment for many hematological malignancies. However, its therapeutic potential is affected by the most prominent side effect graft versus host disease. Despite advances in the treatment of graft versus host disease in recent years, morbidity and mortality remains high, which requires the development of new treatment approaches. We therefore implemented mouse models to assess potential treatment options for graft versus host disease. In in vivo experiments, we had observed a protective effect of LCN2 on graft versus host disease of the gastrointestinal tract. We also observed higher numbers of anti-inflammatory macrophages in the intestinal tissues of these animals. Therefore, we aimed to determine potentially regulated genes in these cells by using an in vitro approach of LCN2-treated macrophages.